Form 4: Werewolf Therapeutics Insider Sells Shares

Ansbert Gadicke, a Director and 10% owner of Werewolf Therapeutics, Inc., along with affiliated entities, reported the sale of 276,017 shares of common stock over three days in late October 2025.

Summary

• Ansbert Gadicke, a Director and 10% owner, and several affiliated entities (MPM BioImpact LLC, MPM Oncology Innovations Fund LP, UBS Oncology Impact Fund L.P., etc.) reported sales of Werewolf Therapeutics, Inc. common stock.
• A total of 276,017 shares were sold across three transactions from October 27 to October 29, 2025.
• The sales were executed pursuant to a Rule 10b5-1 trading plan established on September 24, 2025.
• The weighted average sale prices were $1.72 on October 27, 2025, $1.64 on October 28, 2025, and $1.55 on October 29, 2025.
• Following these transactions, the beneficial ownership of the reporting persons decreased from 6,645,961 shares to 6,442,653 shares.

Sentiment

Score: 3

Explanation: Significant insider selling by a director and major shareholder, even if pre-planned, generally signals a negative outlook or a belief that the stock is fully valued or overvalued. The declining sale prices further reinforce this.

Negatives

• Significant insider selling by a director and 10% owner, along with affiliated investment funds.
• The sales occurred at declining weighted average prices ($1.72, $1.64, $1.55) over three consecutive days.
• A substantial reduction in beneficial ownership by key insiders.

Risks

• Potential negative signal to the market regarding the company's future prospects or valuation from significant insider selling.
• Increased selling pressure on the stock due to the volume of shares sold.

Future Outlook

No specific forward-looking statements or guidance regarding the company's performance were provided. The execution of sales under a Rule 10b5-1 plan suggests a pre-determined selling strategy that may continue.

Management Comments

• Transactions were effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025.

Industry Context

Insider selling is a common occurrence across all industries, often for personal financial planning or portfolio rebalancing. In the biotechnology sector, which is highly sensitive to investor sentiment and clinical trial outcomes, significant insider selling, even if pre-planned, can sometimes be interpreted as a signal regarding future prospects or valuation, potentially impacting investor confidence.

Comparison to Industry Standards

• While 10b5-1 plans are standard practice for insiders to manage stock sales compliantly, the volume of shares sold (276,017 shares) by a director and 10% owner, along with affiliated funds, represents a notable reduction in their beneficial ownership.
• The declining weighted average sale prices ($1.72, $1.64, $1.55) over consecutive days could be viewed less favorably compared to sales at stable or increasing prices, potentially indicating a belief that the stock's value is not appreciating or may face headwinds.
• Without specific comparable insider selling events from direct competitors or similar-stage biotech companies, a direct benchmark is challenging. However, sustained insider selling often contrasts with periods of strong company performance where insiders might hold or even acquire more shares.

Corporate Governance

Related Party Transactions

• The sales were conducted by Ansbert Gadicke and several entities (MPM BioImpact LLC, MPM Oncology Innovations Fund LP, UBS Oncology Impact Fund L.P., Oncology Impact Fund (Cayman) Management L.P., MPM Oncology Innovations Fund GP LLC, MPM Asset Management LLC) where Mr. Gadicke holds various management and membership roles, indicating these are related party dealings.

Stakeholder Impact

• Shareholders may perceive the insider selling as a negative signal, potentially leading to decreased investor confidence and downward pressure on the stock price.
• Potential impact on market sentiment for Werewolf Therapeutics, Inc. due to the actions of a significant insider and institutional investor.

Next Steps

• The existence of a Rule 10b5-1 plan suggests that further sales by these reporting persons may occur in the future.
• Investors will likely monitor subsequent Form 4 filings for Werewolf Therapeutics, Inc. to observe any continuation of insider selling or potential insider buying activity.

Key Dates

Recommendation

The substantial insider selling by a director and 10% owner, particularly at declining prices, suggests that those closest to the company may believe the stock is fully valued or that future prospects are not as strong as previously anticipated. While executed under a 10b5-1 plan, the sheer volume and consistent selling pattern warrant caution. Investors should consider this a negative signal and potentially reduce exposure or avoid initiating new positions until more positive catalysts emerge or insider sentiment shifts.

Keywords

Werewolf Therapeutics, HOWL, Ansbert Gadicke, insider selling, Form 4, beneficial ownership, 10b5-1 plan, common stock, director, 10% owner, MPM BioImpact, UBS Oncology